Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Metastatic squamous neck cancer with occult primary
Stage/Subtype:  untreated metastatic squamous neck cancer with occult primary
Country:  U.S.A.
Trial Type:  Treatment
Results 1-23 of 23 for your search:
Start Over
A Study in Advanced Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13420, NCI-2012-01213, I4E-MC-JXBB, NCT01063075
Combination Chemotherapy with or without Erlotinib Hydrochloride in Treating Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-0395, NCI-2011-03782, NCT01064479
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Dose-escalation Study of Oral CX-4945
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C4-08-001, NCI-2009-01571, NCT00891280
Everolimus, Cisplatin, and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-342, NCI-2010-00294, NCT01058408
A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 115717, NCI-2012-01219, NCT01458067
Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11105, NCI-2012-01040, CDR0000737061, NCI-2013-01545, P9008_A10PAMDREVW01, 9008, NCT01638533
Recombinant Interleukin-15 in Treating Patients with Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN11-02, NCI-2012-02205, NCT01727076
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMP-514-01, NCI-2014-00418, D6020C00002 (AMP-514-01), MEDI0680, NCT02013804
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA186-018, NCI-2014-01698, NCT02110082
Buparlisib, Cisplatin, and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-008, NCI-2014-02351, NCT02113878
A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D6050C00001, NCI-2014-01960, NCT02221960
Cetuximab, BYL719, and Intensity-Modulated Radiation Therapy in Treating Patients with Stage III-IVB Head and Neck Squamous Cell Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-116, NCI-2014-02290, NCT02282371
A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B0601002, NCI-2015-00761, 2014-004107-75, NCT02315066
Radiation Therapy and Pembrolizumab in Treating Patients with Head and Neck Cancer, Kidney Cancer, Melanoma, or Non-small Cell Lung Cancer That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14P.524, NCI-2014-02432, 2014-085, 6980, MK-3475, NCT02318771
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M14-429, NCI-2015-00519, 2014-003557-34, NCT02365662
PCA062 in pCAD-positive Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPCA062X2101, NCI-2015-00491, 2014-003732-40, NCT02375958
Stereotactic Body Radiation Therapy in Treating Patients with High Risk Locally Advanced Head and Neck Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 8314, NCI-2014-02279, NCT02388932
Safety Study of AMG 228 to Treat Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 20140131, NCI-2015-00786, NCT02437916
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 229812, NCI-2013-01198, NCT01896778
Image-Guided Cryoablation in Treating Patients with Head, Neck, and Spine Tumors
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: 13-458, NCI-2014-00949, NCT02085941
Start Over